Optimizing denileukin diftitox (Ontak) therapy.

Article Details

Citation

Copy to clipboard

Duvic M, Talpur R

Optimizing denileukin diftitox (Ontak) therapy.

Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.

PubMed ID

18684057 [ View in PubMed

]

Abstract

Denileukin diftitox (Ontak) is a novel recombinant fusion protein consisting of peptide sequences for the enzymatically active and membrane translocation domain of diphtheria toxin linked to human IL-2. Denileukin diftitox specifically binds to IL-2 receptors on the cell membrane, is internalized via receptor-mediated endocytosis and inhibits protein synthesis by ADP ribosylation of elongation factor 2, resulting in cell death. This article focuses on the clinical trial that led to the US FDA approval of the drug for cutaneous T-cell lymphoma in 1999, and other investigational studies for hematologic malignancies, recurrent and refractory chronic lymphocytic leukemia, non-Hodgkin B-cell lymphoma, graft-versus-host disease and autoimmune disease, demonstrating the activity and adverse effects of the drug.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Denileukin diftitox	Interleukin-2 receptor subunit alpha	Protein	Humans	Yes	Binder	Details
Denileukin diftitox	Interleukin-2 receptor subunit beta	Protein	Humans	Yes	Agonist	Details